Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Epidiolex 100 mg/mL Oral Solution Clear all
Active, not recruiting Phase 4 Interventional

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

NCT05044819
View directory record Official record
Conditions
Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
Interventions
Cannabidiol
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
26
States / cities
Little Rock, Arkansas • Downey, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 26, 2026, 4:41 PM EDT
Recruiting Phase 2 Interventional

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

NCT05269628
View directory record Official record
Conditions
Multiple Sclerosis, Sleep, Pain
Interventions
Cannabidiol (CBD), Tetrahydrocannabinol (THC), Placebo CBD, Placebo THC
Drug
Lead sponsor
Tiffany J. Braley, MD, MS
Other
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 26, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

NCT02544750
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Seizures
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Sep 26, 2026, 4:41 PM EDT
Completed Phase 1 Interventional Results available

University of Alabama at Birmingham (UAB) Pediatric CBD Program

NCT02695537
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Epidiolex
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 19 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Sep 26, 2026, 4:41 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Oral Cannabidiol for Opioid Withdrawal

NCT04238754
View directory record Official record
Conditions
Opioid Withdrawal, Opioid Craving, Opioid Use Disorder
Interventions
Epidiolex, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 26, 2026, 4:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cannabidiol and CES1 Interactions in Healthy Subjects

NCT04603391
View directory record Official record
Conditions
Drug Interaction
Interventions
dl-Methylphenidate plus Cannabidiol, dl-Methylphenidate plus Cannabidiol Placebo solution
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Sep 26, 2026, 4:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study

NCT07298408
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies
Interventions
Cannabidiol (CBD) oral solution, Full-Spectrum CBD hemp extract oral solution, Placebo in MCT oil oral solution
Drug
Lead sponsor
Florida A&M University
Other
Eligibility
40 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 26, 2026, 4:41 PM EDT
Recruiting Phase 2 Interventional

Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber Syndrome

NCT07778810
View directory record Official record
Conditions
Sturge - Weber Syndrome (SWS)
Interventions
Epidiolex 100 mg/mL Oral Solution
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Month to 18 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 26, 2026, 4:41 PM EDT
Recruiting Phase 3 Interventional

Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

NCT04411225
View directory record Official record
Conditions
Early Psychosis
Interventions
Cannabidiol oral solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
16 Years to 30 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 26, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).

NCT04721691
View directory record Official record
Conditions
Electrical Status Epilepticus of Slow-Wave Sleep
Interventions
Epidiolex 100 mg/mL Oral Solution, Placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
2 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 26, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

NCT02224690
View directory record Official record
Conditions
Epilepsy, Lennox-Gastaut Syndrome
Interventions
GWP42003-P 20 mg/kg/day Dose, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 55 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 26, 2026, 4:41 PM EDT
Not yet recruiting Phase 4 Interventional

A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS

NCT07728097
View directory record Official record
Conditions
Lennox-Gastaut Syndrome
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 26, 2026, 4:41 PM EDT
Completed Phase 1 Interventional Results available

University of Alabama at Birmingham (UAB) Adult CBD Program

NCT02700412
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Epidiolex
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 26, 2026, 4:41 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Cannabidiol in Sanfilippo Syndrome

NCT06333041
View directory record Official record
Conditions
Sanfilippo Syndrome, Mucopolysaccharidosis III
Interventions
Epidiolex, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
4 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 26, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease

NCT02818777
View directory record Official record
Conditions
Parkinson's Disease
Interventions
cannabidiol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 26, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional Results available

Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

NCT04421456
View directory record Official record
Conditions
Schizophrenia
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Garden Grove, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 26, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

NCT02224703
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P, Placebo Control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 26, 2026, 4:41 PM EDT
Terminated Phase 3 Interventional Results available

A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

NCT04252586
View directory record Official record
Conditions
Rett Syndrome, RTT
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • La Jolla, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2022 · Synced Sep 26, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

NCT02091375
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P 20 mg/kg/day Dose, Placebo control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
13
States / cities
Miami, Florida • Orlando, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 26, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder

NCT04982029
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Cannabidiol 100 MG/ML [Epidiolex], Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Boston, Massachusetts • Rutland, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 26, 2026, 4:41 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Cannabidiol for Alcohol Use Disorder

NCT03904849
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 26, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

NCT02091206
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P 5 mg/kg/day Dose, Placebo control, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
4 Years to 10 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 26, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

NCT04745026
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 26, 2026, 4:41 PM EDT
Terminated Phase 4 Interventional Results available

Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain

NCT03891264
View directory record Official record
Conditions
Back Pain, Low
Interventions
Cannabidiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Sep 26, 2026, 4:41 PM EDT